The normal counterparts of mantle cell lymphoma (MCL) are naive, quiescent B cells that have not been processed through the germinal center (GC). For this reason, although lymphomas arising from GC or post-GC B cells often exhibit plasmacytic differentiation, MCL rarely presents with plasmacytic features. Seven cases of MCL with a monotypic plasma cell (PC) population were collected from 6 centers and were studied by immunohistochemistry, fluorescence immunophenotyping and interphase cytogenetics as a tool for the investigation of neoplasms analysis, capillary gel electrophoresis, and restriction fragment length polymorphism of immunoglobulin heavy chain analysis of microdissections of each of the MCL and PC populations to assess their clonal relationship. The clinical presentation was rather unusual compared with typical MCL, with 2 cases arising from the extranodal soft tissues of the head. All MCL cases were morphologically and immunohistochemically typical, bearing the t(11;14)(q13;q32). In all cases, the PC population was clonal. In 5 of the 7 cases, the MCL and PC clones showed identical restriction fragments, indicating a common clonal origin of the neoplastic population. The 2 cases with clonal diversity denoted the coexistence of 2 different tumors in a composite lymphoma/PC neoplasm. Our findings suggest that MCL can present with a PC component that is often clonally related to the lymphoma, representing a rare but unique biological variant of this tumor.
M antle cell lymphoma (MCL) accounts for approximately 7% of all B-cell lymphomas in North America. 1, 43 Its median age of diagnosis is approximately 60 years, and patients usually present with bone marrow involvement and with advanced-stage disease, the spleen and gastrointestinal tract being the most frequently involved sites. Although the overall response rate to chemoimmunotherapy is usually good, relapses are frequent and the prognosis is poor, with a median overall survival of 3 to 5 years. 15 MCL is characterized by a nodular and/or diffuse histologic growth pattern and by different cytologic subtypes (classical, small cell, pleomorphic, and blastoid). 5, 42 The neoplastic cells typically are CD20 + , CD5 + , CD43 + , CD23 À , CD3 À , CD10 À , and FMC7 + . These are characterized by the presence of the t(11;14)(q13;q32), which results in the overexpression of cyclin D1. 31, 34 A small fraction of MCL may not express cyclin D1 13 and it might be difficult to distinguish from other small B-cell lymphomas. Recently, overexpression of the nuclear transcription factor, sox11 mRNA, and of its nuclear protein, has been reported as a specific marker for both cyclin D1-positive and cyclin D1-negative MCL. 28 Plasma cells (PCs) are usually absent in MCL or, if present, present in extremely small numbers. They have traditionally been regarded as part of the non-neoplastic background, being formally polyclonal. MCL develops from naive B cells that reside in primary lymphoid follicles and the mantle zones of secondary follicles that have still not undergone the germinal center (GC) process. 36 This process starts when antigen recognition, together with signals from the surrounding T cells, activates GC B cells to undergo somatic hypermutation and class-switch recombination, and to proliferate and differentiate within the GC. The GC B cells expressing a high-affinity immunoglobulin at the end of the process will be preferentially selected for survival and will differentiate into PCs or memory B cells. 18 Thus, it is not surprising that plasmacytic differentiation has been described in several B-cell lymphomas arising from B cells at the GC or post-GC developmental stage, such as diffuse large B-cell lymphoma, 27 follicular lymphoma, 16 and marginal zone lymphoma. 20 In lymphoplasmacytic lymphomas, the malignant clone shows a wide morphologic heterogeneity ranging from small B lymphocytes to PCs, although little is known about its cell of origin. 17 Among pre-GC-deriving lymphomas, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) 9, 14, 47 and MCL 29, 46 have also been described to occasionally show plasmacytic differentiation.
In this study, we report 7 cases of classical MCL recruited from 6 medical centers, which exhibited monotypic PC proliferation. Both the MCL cells and the PCs were analyzed with immunohistochemistry and separated by microdissection to characterize them by means of fluorescence immunophenotyping and interphase cytogenetics as a tool for the investigation of neoplasms (FICTION) analysis, capillary gel electrophoresis, and immunoglobulin heavy chain variable region restriction fragment length polymorphism (RFLP/IgH). We found that PCs were usually clonal, and that they originated from the same neoplastic B-cell clone as MCL in the majority of cases.
MATERIALS AND METHODS

Histology and Immunohistochemistry
All specimens were obtained at the first presentation of the lymphoma and consisted of lymph nodes (1 case), periorbital mass (1), appendix (1), spleen (1), and nasal mass (1). In the remaining 2 cases, the 2 cell populations (MCL and PCs) were analyzed on lymph node and bone marrow, respectively, due to the predominance of each population in the 2 different tissues. The specimens were collected at the University of Wisconsin (2 cases), the University of California San Diego School of Medicine (1), the British Columbia Cancer Agency (1), the University of Pittsburgh School of Medicine (1), the Autonomous University of Barcelona (1), and Ingham Regional Medical Center at Michigan (1) . The specimens were fixed in 10% neutral-buffered formalin, embedded in paraffin, and 4-mm-thick sections were cut and stained with hematoxylin and eosin for histologic evaluation. Immunohistochemical stains were also performed on the formalin-fixed, paraffin-embedded tissue sections. In brief, after deparaffinization in xylene and rehydration in graded alcohols, endogenous peroxidase was blocked Left axillary lymph  node  AAS  I  IV  IV  IV  III-IV  IV  IV  B with 3% hydrogen peroxide. Antigen retrieval was performed in citrate buffer, pH 6.0, as appropriate for the antibodies. After rinsing in phosphate-buffered saline, antibodies against CD3, CD5, CD10, CD20, CD23, CD43, CD138, BCL2, BCL6, k and l light chains, IgG, IgM, and cyclin D1 were used for immunohistochemical stains. These stains were performed on a Ventana ES automated immunostainer (Ventana Biotek, Tucson, AZ) using a streptavidin-biotin peroxidase detection system. The source of the antibodies was Ventana for CD3, CD10, CD43, and k and l light chains (PS1, 56C6, L60 clones, respectively, polyclonal k and l), Novocastra for CD5 (4C7 clone), DAKO for CD20, Bcl-2, Bcl-6 (L26, 124, PG-B6p clones, respectively), the binding site for CD23 (BU38 clone), Neomarkers for cyclin D1 (SP4 clone), and DakoCytomation for CD138 (MI15 clone).
FISH Analysis
Interphase fluorescence in situ hybridization (FISH) analysis was carried out on the formalin-fixed, paraffinembedded tissue sections by codenaturation of the probe and target DNA using the HybRite system (Vysis, Inc) at 801C for 5 minutes. Then, hybridization of the probe with the target DNA at 371C overnight, followed by a posthybridization wash (2xSSC/0.1% NP40) at 721C for 2 minutes and a room temperature (RT) wash (2xSSC/ 0.1% NP40) for 1 minute and then counterstaining with DAPI II (Abbott/Vysis, Inc.) was carried out. For detection of the t (11;14) , commercially available LSI IgH/CCND1 XT Dual-Color, Dual Fusion Translocation Probe (Abbott/Vysis, Inc.) was used. The observed fusion signals were considered to be significant if they were in greater than 8% of the cells, the cutoff determined by the study of 20 normal tissue specimens in our laboratory.
FICTION Analysis
Immunofluorescence combined with interphase FISH analysis for the t(11;14)(q13;q32) was performed as described earlier with minor modifications. 25, 41 The staining for either immunoglobulin light chains or CD138 was performed before the interphase FISH procedure. The assay was carried out on the formalin-fixed, paraffinembedded tissue sections using a fluorescein (FITC)streptavidin-biotin detection system. In brief, after deparaffinization and rehydration, the sections were pretreated with 10-mM citrate buffer, pH 6.0, in a pressure cooker for 8 minutes, followed by boiling for 12 minutes for antigen retrieval. The sections were then incubated with a blocking buffer (50 mM Tris-HCl, pH 8.2, containing 5% bovine serum albumin, and 5% normal goat serum) at RT for 20 minutes. Primary antibodies (goat antihuman k/l light chain or CD138; Sigma, St Louis, MO) were then applied, and after 3 washes, were covered with FITC-labeled, secondary antibody (rabbit antigoat IgG; Vector Labs, Burlingame, CA). Tertiary antibody (biotinylated goat anti-FITC IgG; Vector Labs) were applied at a concentration of 20 mg/mL in 1 Â phosphate-buffered saline, pH 7.4, at RT for 30 minutes. The FITC-anti-FITC complexes were then detected by incubation with FITC-labeled streptavidin (Vector Labs). The sections were postfixed in 1% paraformaldehyde at 41C for 20 minutes, and the slides were processed for hybridization with t(11;14) FISH probe and were covered with an Aqua Mount Medium. At least 100 cells were then evaluated by fluorescence microscopy for light chains or CD138 expression and the t(11;14) as described earlier. 41 The frequency of t(11;14) fusion signals in IgL or CD138-positive and CD138negative cells was quantitated.
Immunoglobulin Variable Region RFLP/IgH
The analysis was carried out as described earlier. 39 In brief, genomic DNA was extracted separately from the CD138 + and CD5 + tumor cells, which were microdissected from the formalin-fixed, paraffin-embedded tissue sections using a Genovison extraction kit (Qiagen, Germany) as described by Fong et al. 10 Polymerase chain reaction (PCR) assays for IgH gene rearrangement was performed using consensus FR1 and FR3 and J primers, as published earlier. 26 DNA from normal or polyclonal B-cell population produced a bell-shaped curve of amplicon products (Gaussian distribution) and was used as a control. Clonal rearrangements were identified as prominent, single-sized amplification products. Examination of PCR products was carried out with highresolution fragment length analysis (ABI 310 Genetic Analyzer, Applied Biosystems).
Capillary Gel Electrophoresis of the PCR Products
The IgH genes were amplified using a seminested PCR method with a primer complementary to the FR3 and 2 primers hybridizing the antisense J H region. The primer sequences used to amplify the IgH genes by a seminested PCR method were the following: 5 0 ACC TGA GGA GAC GGT GAC C3 0 for J H external, Genbank accession AY180386.1, base pairs 342 to 342; 5 0 ACC AGG GTC CCT TGG CCC CA3 0 for J H nested, Genbank accession AF343422, base pairs 289 to 308; 5 0 CTG TCG ACA CGG CCG TGT ATT ACT G3 0 for V670, Genbank accession AB067303.1, base pairs 263 to 
RESULTS
Clinical Features
Median age of the 7 patients was 74 years (range, 62 to 91 y), and 4 were male patients. All patients except 1 presented with advanced-stage disease and bone marrow involvement either by MCL (cases 3, 4, and 8) or by both clonal PCs and MCL (cases 2, 6, and 7). Two cases presented with a mass arising from soft tissues of the head, and 1 of them had tumor limited to this site (Table 1) . Clinical presentation seemed to be more dictated by the natural history of the MCL component rather than of multiple myeloma, as bone lytic lesions and renal failure due to light chain deposition were observed in only 1 patient (case 2). Serum and urine electrophoresis revealed a monoclonal component in 3 of the patients, as reported in Table 1 .
Treatment of patients varied, including both myeloma-directed and lymphoma-directed therapies, but the response to treatment and overall survival were quite poor. Although not reaching statistical significance due to the small number of patients analyzed, specific myelomadirected therapies seemed to be less effective than common immunochemotherapy regimens usually used to treat MCL patients. Although active in both diseases, but primarily used for treating multiple myeloma, Velcade, Thalidomide, and Lenalidomide were ineffective or induced transitory responses in all 4 patients treated with these drugs. Of note, the patient presenting with a localized tumor (nasal mass, case 1) was treated with surgical resection followed by radiotherapy alone (50 Gy), and achieved a long-lasting complete remission.
Histology and Immunohistochemistry
All cases were reviewed by at least 3 hematopathologists (K.H.Y., J.T.M., and primary contributing pathologists), and were classified as typical MCL in terms of cytology, histology, and immunohistochemistry ( Figs. 1-4) . The histologic growth pattern was mantle zone (2), nodular (3), diffuse (2), including 1 pleomorphic-blastoid cytologic subtype. The MCL components from all cases had the characteristic MCL phenotype: CD20 + , CD5 + , CD3 À , cyclin D1 + , CD23 À , and CD138 À . Immunoglobulin heavy chain expression lacked in all cases of MCL cells, probably due to the low sensitivity of immunohistochemical staining in this setting. The PCs were all CD20 À and CD138 + , and exhibited cytoplasmic k light chain restriction in 2 cases, l in 4 cases, whereas 1 case was indeterminate but expressed IgM heavy chain (case 7). As described in Figures 1 to 4 , PCs from all cases showed typical morphology with rare mitotic figures and were focally positive for cyclin D1 in 2 patients (cases 2 and 6; Table 2 ). In 5 cases, sheets of PCs were observed within the neoplastic lymphoid tissue, whereas in 2 patients (cases 2 and 7) clonal PCs were confined to the bone marrow together with lymphoma localization of an otherwise typical nodal MCL.
When analyzed by immunohistochemistry ( Table 2) , only 3 cases showed identical monotypic immunoglobulin light chain expression between MCL and PCs (cases 2, 4, and 6), confirming that this method is not reliable and has low sensitivity in identifying relationships among different clones.
RFLP/IgH, Capillary Gel Electrophoresis, and FICTION Analysis
The combination of these 3 analyses allowed us to investigate the 2 cell populations (MCL cells and PCs) individually in terms of clonality, relationship between clones, and cytogenetics. The rationale for the use of RFLP/IgH methodology was that each B cell has a single productive immunoglobulin gene rearrangement that is unique in both length and sequence. According to RFLP/ IgH assay results on microdissected CD138 + and CD5 + tumor cells, which are exemplified in Figure 5 , all cases exhibited a clonal PC population, and in 5 of 7 cases (71%) the MCL cells and PCs showed identical RFLP/ IgH, indicating that both populations were derived from the same neoplastic B-cell clone (also see Table 1 ). The remaining 2 cases without an identical RFLP/IgH pattern (cases 1 and 5) exhibited distinct peaks by clonal PCs that differed from MCL and may represent a composite MCL and extramedullary plasmacytoma or marginal zone lymphoma with an associated PC component.
As shown in the gel images ( Fig. 6A ), we obtained PCR products from FR3 for all the samples except PC samples of cases 4 and 6. For PC sample of case 6, in which amplification of the FR3 region failed, we successfully amplified FR2, which clearly showed a single band. However, for the PC component of case 4, amplification failed for both regions (Fig. 6A ). As shown in Figure 6B , when we analyzed the FR3 products on better resolution of the amplified DNA fragments by capillary gel electrophoresis, most of the samples had a single monoclonal band, whereas some samples contained multiple clonal bands (MCL of cases 1, 2, and 3 and PC of cases 3 and 7). Overall, as described in Table 2 , for the 5 patients successfully analyzed with gel electrophoresis on both populations of MCL and PC, a complete concordance with the RFLP/IgH analysis was observed.
By FICTION analysis we detected the characteristic t(11;14)(q13;q32) in the MCL component from all 5 cases that were successfully studied, and also in 2 cases (cases 2 and 6) of the PC population (Table 2, Fig. 7 ). Both of these cases were characterized by clonal identity between the 2 clones. In the remaining 3 cases (cases 4 and 7) with clonal identity, the PC clone was negative for the t(11;14)(q13;q32) in case 3, whereas the FICTION analysis failed in cases 4 and 7. Figure 7 reports the FICTION analysis of the 5 cases with available results.
DISCUSSION
Gene expression profiling and other molecular technologies have led us to discriminate the developmental stage of the cell of origin of B-cell lymphoma subtypes. 23 As B-cell lymphomas originate from distinct steps of differentiation of normal B cells, we would expect that some entities would be more prone to differentiate into PCs than others. Indeed, many marginal zone lymphomas and virtually all lymphoplasmacytic lymphomas have a clonal PC component. 7, 8, 21 Others, such as diffuse large B-cell lymphomas, 27, 35 CLL/SLL, 9, 14, 17 and follicular lymphoma 16, 20 may show plasmacytic differentiation, whereas little is known about MCL. 29, 46 With this study we provide strong evidence that clonal PC differentiation can also occur in certain cases of MCL, clearly showing that the PCs and MCL cells can derive from the same B-cell clone.
In this study, we investigated 7 new cases of otherwise typical MCL that showed significant PC population within the tumor tissue. To achieve robust conclusions regarding the relationship between the 2 neoplastic populations, we used PCR for IgH with capillary gel electrophoresis, FICTION, and RFLP/IgH assay for each microdissected MCL and PCs. The molecular analysis for the immunoglobulin heavy chain rearrangement showed an identical clonal origin of the MCL and PC populations in 5 of the 7 samples, indicating that these cases represent an interesting morphologic type of MCL. Results of capillary gel electrophoresis of PCR products were concordant with RFLP/IgH analysis, independently confirming our findings. As shown in Figure 5 , cases 1 and 5 had no clonal relationship between PCs and MCL, and represented a concomitant PC neoplasm or a nodal marginal zone lymphoma and MCL in the same patient. Composite lymphomas consisting of MCL and a clonally unrelated plasmacytoma or PC myeloma have occasionally been reported. 2, 40, 45 The distinction between MCL with a concomitant PC neoplasm and a unique variant of MCL has relevant clinical significance, as prognosis and treatment of the 2 forms of the disease would be expected to be different. A multidisciplinary approach including detailed morphologic evaluation and a panel of immunostains, along with cytogenetic analysis for the This study follows 2 previously published cases 46 describing for the first time the presence of clusters of monotypic k light chain expressing PCs in the center of MCL nodules and within the reactive GCs. In an earlier À À À À À À À À À À À À À À CD20 study, the presence of the t(11;14)(q13;q32) both in the MCL cells and in the clonal PCs was considered as compatible with a common origin from the same B-cell clone. However, the demonstration of the translocation itself in the 2 clones is insufficient to discriminate between MCL with plasmacytic differentiation and MCL with concurrent PC neoplasm, as the t(11;14)(q13;q32) is commonly observed in nonhyperdiploid PC myeloma. 11 More recently, another case of MCL with evidence of clonal plasmacytic differentiation has been reported by Naushad et al, 29 using multiparameter flow cytometry to show a close relationship between the 2 clones. Monoclonal paraproteins, mostly of the IgM type, can be showed in the serum of B-cell lymphoma, mostly in CLL/SLL and marginal zone lymphoma, usually at lower levels than in lymphoplasmacytic lymphoma. 24 Using a sensitive serum immunoassay, monoclonal IgM and IgG were reported earlier in 18% and 5% of patients with MCL, respectively. 32 These findings suggest that clonal PCs can be part of MCL tumor microenvironment, and the frequency of clonal PCs in MCL may be more common than was thought earlier. Among our cases, a monoclonal paraprotein was present in 3 of 7 (43%) patients with a clonal PC population.
During a normal immune response, when naive B cells meet an antigen with adequate affinity, they are selected and induced to proliferate by either entering the GC or extrafollicular areas, where they divide further before differentiating into short-lived PCs. Therefore, plasmacytic differentiation could develop by 2 different pathways: GC (activated B cells) and non-GC (naive B cells). 30 The underlying mechanisms are better understood for the GC pathway in which environmental stimuli may induce the GC B cell to become a PC. As GC B cells begin to differentiate into PC, they upregulate the transcription factor, interferon regulatory factor 4 (IRF4), which initiates plasmacytic differentiation by increasing the expression of B lymphocyte-induced maturation protein 1, 33 and extinguishes the GC B-cell program by repressing BCL6. 38 In this scenario, growth factors (IL-6) and cell-cell interactions (CD40L) play regulatory roles in mediating transcription factor expression and lead to somatic hypermutation of their rearranged IgH genes and finally to PC differentiation. 3, 12, 19 It is generally accepted that most biologically long-lived PCs derive from B cells in the GCs or post-GC marginal zones. Alternatively, PCs can also arise from memory B cells derived from GC centrocytes and can quickly differentiate into PCs through the GC pathway on secondary encounter with minute amounts of antigen. In contrast, little is known regarding plasmacytic differentiation by the non-GC pathway. A proportion of naive B cells can undergo IgH gene mutations outside the GCs without T-cell help and express IgG, but most of them are not switched and express IgM, 37, 44 as observed in CLL/SLL. 6 In vitro studies have confirmed that PCs can differentiate from naive B cells, but they are usually short lived with low-quantity production. 30 Somatic hypermutation and class-switch recombination are critical to PC differentiation through the GC, and require the presence of activation-induced cytidine deaminase, which is virtually absent on naive primary follicle, mantle zone, and extrafollicular B cells. However, a fraction of naive B cells can harbor the mutated IgH gene and express activation-induced cytidine deaminase, suggesting that these cells may be able to enter the GC and differentiate into PCs. 22 It is likely that MCL cells under some circumstances can enter the GC and differentiate into PCs, as outlined in 2 cases of MCL with clusters of clonal PCs within reactive GCs 46 and as suggested by recent reports of IgH gene mutations in a considerable subset of MCL. 4 In this regard, it would be of interest to explore the correlation of IgH gene mutational status in groups of MCL cases with and without PC component, which may in part address the question of GC-mediated versus non-GC-mediated PC differentiation. Further study of similar cases will be needed to better understand these processes.
In conclusion, this study clearly showed the existence of MCL with a related plasmacytic component. Our comprehensive analysis shows that in most MCLs with clonal PCs, the 2 components are clonally related (5/7, 71%), indicating that clonal PC differentiation may occur in most of MCLs in which the PC component is present. However, in some cases the 2 clones are unrelated, being likely a reflection of a composite tumor, whereas the presence of polyclonal PCs within MCL as thought earlier seems rather unusual. A molecular approach to analyze the clonal relationship between the 2 populations is needed to exclude a composite lymphoma and allow for appropriate treatment.
